Shopping Cart 0
Cart Subtotal
USD 0

Perrigo Company Plc (PRGO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Perrigo Company plc (Perrigo) is an over-the-counter consumer goods and specialty pharmaceutical company. It develops, manufactures and distributes over-the-counter products, generic and prescription pharmaceuticals, specialty pharmaceutical company, nutritional products, active pharmaceutical ingredients (APIs) and infant formulas. The company's major products include analgesics, gastrointestinal, personal care and derma therapeutics, colobetasol spray, clindamycin foam, mupirocin ointment, halobetasol ointment and cream and permethrin cream. It markets products through wholesalers, retail drug, supermarket and mass merchandise chains and direct sales representatives. The company has operations in North America, Europe, Australia and other countries including Israel and China. Perrigo is headquartered in Dublin, Ireland.

Perrigo Company Plc (PRGO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Perrigo Company Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Perrigo Company Plc, Medical Devices Deals, 2012 to YTD 2018 13

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deal Details 18

Asset Purchase 18

Perrigo Acquires Remaining 60.9% Rights of Benzaclin from Barr Labs for USD62 Million 18

Perrigo Acquires Generic Dosage Forms of Retin-A from Matawan Pharma 19

Perrigo Acquires US Rights to Entocort from AstraZeneca for USD380 Million 20

Perrigo Acquires ScarAway Brand from Enaltus 21

Perrigo Acquires OTC Brands Portfolio from GlaxoSmithKline Consumer Healthcare for USD226 Million 22

Perrigo Acquires Mexican Operations of Patheon for USD34 Million 23

Perrigo to Acquire Women's Healthcare Business from Lumara Health for USD82 Million 24

Perrigo Acquires OTC Products From Aspen Global For USD 51 Million 26

Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharma For Up To USD 129 Million 27

Omega Pharma Acquires Arterin Business Of Pharco For USD 13 Million 28

Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 29

Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For USD 614 Million 30

Venture Financing 32

Proteostasis Therapeutics Raises USD37 Million in Series B Financing 32

Private Equity 34

SK Capital Partners Acquires Perrigo API Business from Perrigo for USD110 Million 34

Partnerships 35

Sol-Gel Technologies Enters into Agreement with Perrigo Israel Pharma 35

Dompe Farmaceutici Enters into Distribution Agreement with Omega Pharma 36

Paragon BioTeck Enters into Co-Promotion Agreement with Perrigo 37

Sol-Gel Technologies Amended Development Agreement with Perrigo 38

NovaMedica Enters into Co-Marketing Agreement with Omega Pharma 39

Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide 40

Impax Labs Enters Into Co-Development Agreement With Perrigo 41

Omega Pharma Enters Into Co-Marketing Agreement With Kwizda Pharma For BronchoStop Cough Products 42

Omega Pharma Enters Into Joint Venture With Cavi Brands To Form OmegaLabs 43

Omega Pharma Enters Into Co-Development Agreement With Sienna Biotec 44

Licensing Agreements 45

Perrigo Enters into Licensing Agreement with Merck 45

Hikma Pharma Enters into Licensing Agreement with Omega Pharma Trading 46

TLC Therapeutics Enters into Licensing Agreement with Rosemont Pharma 47

Perrigo Enters into Licensing Agreement with Highland Pharma 48

Perrigo Enters into Licensing Agreement with Flamel Ireland 49

BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 50

Perrigo Enters Into Licensing Agreement With Fera Pharma For Neptazane 51

Perrigo Enters into Licensing Agreement with Imago Pharma 52

Equity Offering 53

Perrigo Raises USD1.03 Billion in Public Offering of Shares 53

Prothena Raises USD82.7 Million in Public Offering of Shares 55

Omega Pharma Completes Public Offering Of Shares For USD 237 Million 57

Debt Offering 58

Perrigo Raises USD700 Million in Public Offering of 4.375% Notes Due 2026 58

Perrigo Raises USD500 Million in Public Offering of 3.5% Notes Due 2021 60

Perrigo Raises USD400 Million in Public Offering of 4.9% Senior Notes Due 2044 62

Perrigo Raises USD500 Million in Public Offering of 3.5% Senior Notes Due 2021 64

Perrigo Raises USD700 Million in Public Offering of 3.9% Senior Notes Due 2024 66

Perrigo Completes Private Placement Of Notes Due 2023 For USD 800 Million 68

Perrigo Completes Private Placement Of Notes Due 2043 For USD 400 Million 69

Perrigo Completes Private Placement Of Notes Due 2018 For USD 600 Million 70

Perrigo Completes Private Placement Of Notes Due 2016 For USD 500 Million 71

Omega Pharma Completes Public Offering Of Bonds Due 2017 For USD 383 Million 72

Omega Pharma Completes Public Offering Of Bonds Due 2017 For USD 237.6 Million 73

Omega Pharma Completes Public Offering Of Bonds Due 2019 For USD 158.4 Million 74

Asset Transactions 75

Perrigo to Sell its Prescription Pharma Business 75

Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 76

Custopharm Acquires Two ANDA Pharmaceutical Products from Perrigo 78

IDT Australia to Acquire Synthetic Conjugated Estrogens from Perrigo 79

Medline Industries Acquires Personal Hygiene Business Assets From Perrigo 80

Acquisition 81

Alvogen Acquires Omega Bittner from Perrigo for USD15 Million 81

Strides Shasun Acquires Perrigo API India from Perrigo for USD14.8 Million 82

Perrigo Acquires 100% Stake in Gelcaps Exportadora De Mexico 83

Perrigo Company Acquires Banner Pharmacaps from Patheon for USD36.4 Million 84

Perrigo Acquires Omega Pharma for USD4.76 Billion 85

Perrigo Acquires Remaining 15% Stake in Vedants Drugs & Fine Chemicals 87

Perrigo To Acquire 7% Stake In Transition Therapeutics For USD 15 Million 88

Perrigo Completes Acquisition Of Elan 89

Perrigo Acquires Rosemont Pharma From Close Brothers Private Equity For USD 284 Million 91

Omega Pharma Acquires Naturoteek 93

Perrigo Acquires Remaining 81.5% Stake In Cobrek Pharma For USD 45 Million 94

Couckinvest Completes Acquisition Of Remaining Stake In Omega Pharma For USD 1.26 Billion 95

Perrigo Acquires CanAm Care, Distributor Of Diabetes Care Products, For USD 36 Million 97

Perrigo Company Plc-Key Competitors 98

Perrigo Company Plc-Key Employees 99

Perrigo Company Plc-Locations And Subsidiaries 100

Head Office 100

Other Locations & Subsidiaries 100

Recent Developments 106

Strategy And Business Planning 106

Aug 13, 2018: Perrigo plans separation of Rx business 106

Financial Announcements 108

Aug 09, 2018: Perrigo Company reports second quarter 2018 financial results 108

May 08, 2018: Perrigo Company Announces First Quarter 2018 Financial Results 110

Mar 01, 2018: Perrigo Company Reports Fourth Quarter & Calendar Year 2017 Financial Results 112

Feb 27, 2018: Perrigo Company Reports Select Preliminary Unaudited Calendar Year 2017 Financial Results 114

Nov 09, 2017: Perrigo Company Reports Third Quarter 2017 Financial Results 115

Aug 10, 2017: Perrigo Company Reports Second Quarter 2017 Financial Results 117

May 30, 2017: Perrigo Company Files First Quarter 2017 Form 10-Q And Reports First Quarter 2017 Financial Results 118

May 22, 2017: Perrigo Reports Fourth Quarter 120

Apr 25, 2017: Perrigo Announces Select Preliminary Unaudited First Quarter 2017 Financial Results 123

Feb 27, 2017: Perrigo Company Reports Select Preliminary Unaudited Calendar Year 2016 Financial Results And Initial Calendar Year 2017 Guidance 124

Corporate Communications 126

Oct 08, 2018: Perrigo appoints Murray S. Kessler as President And Chief Executive Officer In line with shift To consumer-focused strategy 126

Feb 20, 2018: Perrigo Appoints Ronald L. Winowiecki as Chief Financial Officer 127

Jan 08, 2018: Perrigo Appoints Uwe Rohrhoff As President & Chief Executive Officer 128

Jun 05, 2017: Perrigo Announces Forthcoming Retirement Of CEO John Hendrickson 129

May 08, 2017: Perrigo Announces Two New Independent Directors 130

Feb 27, 2017: Perrigo Announces Leadership Changes 131

Product News 132

08/16/2017: Perrigo Announces FDA Final Approval for its AB Rated Generic Version of Mycolog II Cream 132

06/19/2017: Perrigo Announces the Launch of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution 133

Mar 08, 2017: Perrigo Announces First-To-Market Launch Of The OTC Store Brand Equivalent To Women's Rogaine Foam 134

02/17/2017: Perrigo Announces FDA Final Approval For Hydrocodone Bitartrate And Homatropine Methylbromide Oral Solution 135

Other Significant Developments 136

Aug 09, 2018: Perrigo announces plan to separate prescription pharmaceuticals business 136

Jan 10, 2017: Perrigo Updates Segment Reporting Structure 137

Appendix 138

Methodology 138

About GlobalData 138

Contact Us 138

Disclaimer 138


List Of Figure

List of Figures

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Perrigo Company Plc, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Perrigo Company Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Perrigo Company Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Perrigo Company Plc, Deals By Therapy Area, 2012 to YTD 2018 11

Perrigo Company Plc, Medical Devices Deals, 2012 to YTD 2018 13

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Perrigo Acquires Remaining 60.9% Rights of Benzaclin from Barr Labs for USD62 Million 18

Perrigo Acquires Generic Dosage Forms of Retin-A from Matawan Pharma 19

Perrigo Acquires US Rights to Entocort from AstraZeneca for USD380 Million 20

Perrigo Acquires ScarAway Brand from Enaltus 21

Perrigo Acquires OTC Brands Portfolio from GlaxoSmithKline Consumer Healthcare for USD226 Million 22

Perrigo Acquires Mexican Operations of Patheon for USD34 Million 23

Perrigo to Acquire Women's Healthcare Business from Lumara Health for USD82 Million 24

Perrigo Acquires OTC Products From Aspen Global For USD 51 Million 26

Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharma For Up To USD 129 Million 27

Omega Pharma Acquires Arterin Business Of Pharco For USD 13 Million 28

Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 29

Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For USD 614 Million 30

Proteostasis Therapeutics Raises USD37 Million in Series B Financing 32

SK Capital Partners Acquires Perrigo API Business from Perrigo for USD110 Million 34

Sol-Gel Technologies Enters into Agreement with Perrigo Israel Pharma 35

Dompe Farmaceutici Enters into Distribution Agreement with Omega Pharma 36

Paragon BioTeck Enters into Co-Promotion Agreement with Perrigo 37

Sol-Gel Technologies Amended Development Agreement with Perrigo 38

NovaMedica Enters into Co-Marketing Agreement with Omega Pharma 39

Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide 40

Impax Labs Enters Into Co-Development Agreement With Perrigo 41

Omega Pharma Enters Into Co-Marketing Agreement With Kwizda Pharma For BronchoStop Cough Products 42

Omega Pharma Enters Into Joint Venture With Cavi Brands To Form OmegaLabs 43

Omega Pharma Enters Into Co-Development Agreement With Sienna Biotec 44

Perrigo Enters into Licensing Agreement with Merck 45

Hikma Pharma Enters into Licensing Agreement with Omega Pharma Trading 46

TLC Therapeutics Enters into Licensing Agreement with Rosemont Pharma 47

Perrigo Enters into Licensing Agreement with Highland Pharma 48

Perrigo Enters into Licensing Agreement with Flamel Ireland 49

BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 50

Perrigo Enters Into Licensing Agreement With Fera Pharma For Neptazane 51

Perrigo Enters into Licensing Agreement with Imago Pharma 52

Perrigo Raises USD1.03 Billion in Public Offering of Shares 53

Prothena Raises USD82.7 Million in Public Offering of Shares 55

Omega Pharma Completes Public Offering Of Shares For USD 237 Million 57

Perrigo Raises USD700 Million in Public Offering of 4.375% Notes Due 2026 58

Perrigo Raises USD500 Million in Public Offering of 3.5% Notes Due 2021 60

Perrigo Raises USD400 Million in Public Offering of 4.9% Senior Notes Due 2044 62

Perrigo Raises USD500 Million in Public Offering of 3.5% Senior Notes Due 2021 64

Perrigo Raises USD700 Million in Public Offering of 3.9% Senior Notes Due 2024 66

Perrigo Completes Private Placement Of Notes Due 2023 For USD 800 Million 68

Perrigo Completes Private Placement Of Notes Due 2043 For USD 400 Million 69

Perrigo Completes Private Placement Of Notes Due 2018 For USD 600 Million 70

Perrigo Completes Private Placement Of Notes Due 2016 For USD 500 Million 71

Omega Pharma Completes Public Offering Of Bonds Due 2017 For USD 383 Million 72

Omega Pharma Completes Public Offering Of Bonds Due 2017 For USD 237.6 Million 73

Omega Pharma Completes Public Offering Of Bonds Due 2019 For USD 158.4 Million 74

Perrigo to Sell its Prescription Pharma Business 75

Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 76

Custopharm Acquires Two ANDA Pharmaceutical Products from Perrigo 78

IDT Australia to Acquire Synthetic Conjugated Estrogens from Perrigo 79

Medline Industries Acquires Personal Hygiene Business Assets From Perrigo 80

Alvogen Acquires Omega Bittner from Perrigo for USD15 Million 81

Strides Shasun Acquires Perrigo API India from Perrigo for USD14.8 Million 82

Perrigo Acquires 100% Stake in Gelcaps Exportadora De Mexico 83

Perrigo Company Acquires Banner Pharmacaps from Patheon for USD36.4 Million 84

Perrigo Acquires Omega Pharma for USD4.76 Billion 85

Perrigo Acquires Remaining 15% Stake in Vedants Drugs & Fine Chemicals 87

Perrigo To Acquire 7% Stake In Transition Therapeutics For USD 15 Million 88

Perrigo Completes Acquisition Of Elan 89

Perrigo Acquires Rosemont Pharma From Close Brothers Private Equity For USD 284 Million 91

Omega Pharma Acquires Naturoteek 93

Perrigo Acquires Remaining 81.5% Stake In Cobrek Pharma For USD 45 Million 94

Couckinvest Completes Acquisition Of Remaining Stake In Omega Pharma For USD 1.26 Billion 95

Perrigo Acquires CanAm Care, Distributor Of Diabetes Care Products, For USD 36 Million 97

Perrigo Company Plc, Key Competitors 98

Perrigo Company Plc, Key Employees 99

Perrigo Company Plc, Subsidiaries 100

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Perrigo Company Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Perrigo Company plc (Perrigo) is an over-the-counter consumer goods and specialty pharmaceutical company. It develops, manufactures and distributes over-the-counter products, generic and prescription pharmaceuticals, specialty pharmaceutical company, nutritional products, active pharmaceutical ingredients (APIs) and infant formulas. The company's major products include analgesics, gastrointestinal, personal care and derma therapeutics, colobetasol spray, clindamycin foam, mupirocin ointment, halobetasol ointment and cream and permethrin cream. It markets products through wholesalers, retail drug, supermarket and mass merchandise chains and direct sales representatives. The company has operations in North America, Europe, Australia and other countries including Israel and China. Perrigo is headquartered in Dublin, Ireland.

Perrigo Company Plc (PRGO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Perrigo Company Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Perrigo Company Plc, Medical Devices Deals, 2012 to YTD 2018 13

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deal Details 18

Asset Purchase 18

Perrigo Acquires Remaining 60.9% Rights of Benzaclin from Barr Labs for USD62 Million 18

Perrigo Acquires Generic Dosage Forms of Retin-A from Matawan Pharma 19

Perrigo Acquires US Rights to Entocort from AstraZeneca for USD380 Million 20

Perrigo Acquires ScarAway Brand from Enaltus 21

Perrigo Acquires OTC Brands Portfolio from GlaxoSmithKline Consumer Healthcare for USD226 Million 22

Perrigo Acquires Mexican Operations of Patheon for USD34 Million 23

Perrigo to Acquire Women's Healthcare Business from Lumara Health for USD82 Million 24

Perrigo Acquires OTC Products From Aspen Global For USD 51 Million 26

Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharma For Up To USD 129 Million 27

Omega Pharma Acquires Arterin Business Of Pharco For USD 13 Million 28

Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 29

Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For USD 614 Million 30

Venture Financing 32

Proteostasis Therapeutics Raises USD37 Million in Series B Financing 32

Private Equity 34

SK Capital Partners Acquires Perrigo API Business from Perrigo for USD110 Million 34

Partnerships 35

Sol-Gel Technologies Enters into Agreement with Perrigo Israel Pharma 35

Dompe Farmaceutici Enters into Distribution Agreement with Omega Pharma 36

Paragon BioTeck Enters into Co-Promotion Agreement with Perrigo 37

Sol-Gel Technologies Amended Development Agreement with Perrigo 38

NovaMedica Enters into Co-Marketing Agreement with Omega Pharma 39

Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide 40

Impax Labs Enters Into Co-Development Agreement With Perrigo 41

Omega Pharma Enters Into Co-Marketing Agreement With Kwizda Pharma For BronchoStop Cough Products 42

Omega Pharma Enters Into Joint Venture With Cavi Brands To Form OmegaLabs 43

Omega Pharma Enters Into Co-Development Agreement With Sienna Biotec 44

Licensing Agreements 45

Perrigo Enters into Licensing Agreement with Merck 45

Hikma Pharma Enters into Licensing Agreement with Omega Pharma Trading 46

TLC Therapeutics Enters into Licensing Agreement with Rosemont Pharma 47

Perrigo Enters into Licensing Agreement with Highland Pharma 48

Perrigo Enters into Licensing Agreement with Flamel Ireland 49

BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 50

Perrigo Enters Into Licensing Agreement With Fera Pharma For Neptazane 51

Perrigo Enters into Licensing Agreement with Imago Pharma 52

Equity Offering 53

Perrigo Raises USD1.03 Billion in Public Offering of Shares 53

Prothena Raises USD82.7 Million in Public Offering of Shares 55

Omega Pharma Completes Public Offering Of Shares For USD 237 Million 57

Debt Offering 58

Perrigo Raises USD700 Million in Public Offering of 4.375% Notes Due 2026 58

Perrigo Raises USD500 Million in Public Offering of 3.5% Notes Due 2021 60

Perrigo Raises USD400 Million in Public Offering of 4.9% Senior Notes Due 2044 62

Perrigo Raises USD500 Million in Public Offering of 3.5% Senior Notes Due 2021 64

Perrigo Raises USD700 Million in Public Offering of 3.9% Senior Notes Due 2024 66

Perrigo Completes Private Placement Of Notes Due 2023 For USD 800 Million 68

Perrigo Completes Private Placement Of Notes Due 2043 For USD 400 Million 69

Perrigo Completes Private Placement Of Notes Due 2018 For USD 600 Million 70

Perrigo Completes Private Placement Of Notes Due 2016 For USD 500 Million 71

Omega Pharma Completes Public Offering Of Bonds Due 2017 For USD 383 Million 72

Omega Pharma Completes Public Offering Of Bonds Due 2017 For USD 237.6 Million 73

Omega Pharma Completes Public Offering Of Bonds Due 2019 For USD 158.4 Million 74

Asset Transactions 75

Perrigo to Sell its Prescription Pharma Business 75

Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 76

Custopharm Acquires Two ANDA Pharmaceutical Products from Perrigo 78

IDT Australia to Acquire Synthetic Conjugated Estrogens from Perrigo 79

Medline Industries Acquires Personal Hygiene Business Assets From Perrigo 80

Acquisition 81

Alvogen Acquires Omega Bittner from Perrigo for USD15 Million 81

Strides Shasun Acquires Perrigo API India from Perrigo for USD14.8 Million 82

Perrigo Acquires 100% Stake in Gelcaps Exportadora De Mexico 83

Perrigo Company Acquires Banner Pharmacaps from Patheon for USD36.4 Million 84

Perrigo Acquires Omega Pharma for USD4.76 Billion 85

Perrigo Acquires Remaining 15% Stake in Vedants Drugs & Fine Chemicals 87

Perrigo To Acquire 7% Stake In Transition Therapeutics For USD 15 Million 88

Perrigo Completes Acquisition Of Elan 89

Perrigo Acquires Rosemont Pharma From Close Brothers Private Equity For USD 284 Million 91

Omega Pharma Acquires Naturoteek 93

Perrigo Acquires Remaining 81.5% Stake In Cobrek Pharma For USD 45 Million 94

Couckinvest Completes Acquisition Of Remaining Stake In Omega Pharma For USD 1.26 Billion 95

Perrigo Acquires CanAm Care, Distributor Of Diabetes Care Products, For USD 36 Million 97

Perrigo Company Plc-Key Competitors 98

Perrigo Company Plc-Key Employees 99

Perrigo Company Plc-Locations And Subsidiaries 100

Head Office 100

Other Locations & Subsidiaries 100

Recent Developments 106

Strategy And Business Planning 106

Aug 13, 2018: Perrigo plans separation of Rx business 106

Financial Announcements 108

Aug 09, 2018: Perrigo Company reports second quarter 2018 financial results 108

May 08, 2018: Perrigo Company Announces First Quarter 2018 Financial Results 110

Mar 01, 2018: Perrigo Company Reports Fourth Quarter & Calendar Year 2017 Financial Results 112

Feb 27, 2018: Perrigo Company Reports Select Preliminary Unaudited Calendar Year 2017 Financial Results 114

Nov 09, 2017: Perrigo Company Reports Third Quarter 2017 Financial Results 115

Aug 10, 2017: Perrigo Company Reports Second Quarter 2017 Financial Results 117

May 30, 2017: Perrigo Company Files First Quarter 2017 Form 10-Q And Reports First Quarter 2017 Financial Results 118

May 22, 2017: Perrigo Reports Fourth Quarter 120

Apr 25, 2017: Perrigo Announces Select Preliminary Unaudited First Quarter 2017 Financial Results 123

Feb 27, 2017: Perrigo Company Reports Select Preliminary Unaudited Calendar Year 2016 Financial Results And Initial Calendar Year 2017 Guidance 124

Corporate Communications 126

Oct 08, 2018: Perrigo appoints Murray S. Kessler as President And Chief Executive Officer In line with shift To consumer-focused strategy 126

Feb 20, 2018: Perrigo Appoints Ronald L. Winowiecki as Chief Financial Officer 127

Jan 08, 2018: Perrigo Appoints Uwe Rohrhoff As President & Chief Executive Officer 128

Jun 05, 2017: Perrigo Announces Forthcoming Retirement Of CEO John Hendrickson 129

May 08, 2017: Perrigo Announces Two New Independent Directors 130

Feb 27, 2017: Perrigo Announces Leadership Changes 131

Product News 132

08/16/2017: Perrigo Announces FDA Final Approval for its AB Rated Generic Version of Mycolog II Cream 132

06/19/2017: Perrigo Announces the Launch of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution 133

Mar 08, 2017: Perrigo Announces First-To-Market Launch Of The OTC Store Brand Equivalent To Women's Rogaine Foam 134

02/17/2017: Perrigo Announces FDA Final Approval For Hydrocodone Bitartrate And Homatropine Methylbromide Oral Solution 135

Other Significant Developments 136

Aug 09, 2018: Perrigo announces plan to separate prescription pharmaceuticals business 136

Jan 10, 2017: Perrigo Updates Segment Reporting Structure 137

Appendix 138

Methodology 138

About GlobalData 138

Contact Us 138

Disclaimer 138


List Of Figure

List of Figures

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Perrigo Company Plc, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Perrigo Company Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Perrigo Company Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Perrigo Company Plc, Deals By Therapy Area, 2012 to YTD 2018 11

Perrigo Company Plc, Medical Devices Deals, 2012 to YTD 2018 13

Perrigo Company Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Perrigo Acquires Remaining 60.9% Rights of Benzaclin from Barr Labs for USD62 Million 18

Perrigo Acquires Generic Dosage Forms of Retin-A from Matawan Pharma 19

Perrigo Acquires US Rights to Entocort from AstraZeneca for USD380 Million 20

Perrigo Acquires ScarAway Brand from Enaltus 21

Perrigo Acquires OTC Brands Portfolio from GlaxoSmithKline Consumer Healthcare for USD226 Million 22

Perrigo Acquires Mexican Operations of Patheon for USD34 Million 23

Perrigo to Acquire Women's Healthcare Business from Lumara Health for USD82 Million 24

Perrigo Acquires OTC Products From Aspen Global For USD 51 Million 26

Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharma For Up To USD 129 Million 27

Omega Pharma Acquires Arterin Business Of Pharco For USD 13 Million 28

Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 29

Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For USD 614 Million 30

Proteostasis Therapeutics Raises USD37 Million in Series B Financing 32

SK Capital Partners Acquires Perrigo API Business from Perrigo for USD110 Million 34

Sol-Gel Technologies Enters into Agreement with Perrigo Israel Pharma 35

Dompe Farmaceutici Enters into Distribution Agreement with Omega Pharma 36

Paragon BioTeck Enters into Co-Promotion Agreement with Perrigo 37

Sol-Gel Technologies Amended Development Agreement with Perrigo 38

NovaMedica Enters into Co-Marketing Agreement with Omega Pharma 39

Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide 40

Impax Labs Enters Into Co-Development Agreement With Perrigo 41

Omega Pharma Enters Into Co-Marketing Agreement With Kwizda Pharma For BronchoStop Cough Products 42

Omega Pharma Enters Into Joint Venture With Cavi Brands To Form OmegaLabs 43

Omega Pharma Enters Into Co-Development Agreement With Sienna Biotec 44

Perrigo Enters into Licensing Agreement with Merck 45

Hikma Pharma Enters into Licensing Agreement with Omega Pharma Trading 46

TLC Therapeutics Enters into Licensing Agreement with Rosemont Pharma 47

Perrigo Enters into Licensing Agreement with Highland Pharma 48

Perrigo Enters into Licensing Agreement with Flamel Ireland 49

BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 50

Perrigo Enters Into Licensing Agreement With Fera Pharma For Neptazane 51

Perrigo Enters into Licensing Agreement with Imago Pharma 52

Perrigo Raises USD1.03 Billion in Public Offering of Shares 53

Prothena Raises USD82.7 Million in Public Offering of Shares 55

Omega Pharma Completes Public Offering Of Shares For USD 237 Million 57

Perrigo Raises USD700 Million in Public Offering of 4.375% Notes Due 2026 58

Perrigo Raises USD500 Million in Public Offering of 3.5% Notes Due 2021 60

Perrigo Raises USD400 Million in Public Offering of 4.9% Senior Notes Due 2044 62

Perrigo Raises USD500 Million in Public Offering of 3.5% Senior Notes Due 2021 64

Perrigo Raises USD700 Million in Public Offering of 3.9% Senior Notes Due 2024 66

Perrigo Completes Private Placement Of Notes Due 2023 For USD 800 Million 68

Perrigo Completes Private Placement Of Notes Due 2043 For USD 400 Million 69

Perrigo Completes Private Placement Of Notes Due 2018 For USD 600 Million 70

Perrigo Completes Private Placement Of Notes Due 2016 For USD 500 Million 71

Omega Pharma Completes Public Offering Of Bonds Due 2017 For USD 383 Million 72

Omega Pharma Completes Public Offering Of Bonds Due 2017 For USD 237.6 Million 73

Omega Pharma Completes Public Offering Of Bonds Due 2019 For USD 158.4 Million 74

Perrigo to Sell its Prescription Pharma Business 75

Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 76

Custopharm Acquires Two ANDA Pharmaceutical Products from Perrigo 78

IDT Australia to Acquire Synthetic Conjugated Estrogens from Perrigo 79

Medline Industries Acquires Personal Hygiene Business Assets From Perrigo 80

Alvogen Acquires Omega Bittner from Perrigo for USD15 Million 81

Strides Shasun Acquires Perrigo API India from Perrigo for USD14.8 Million 82

Perrigo Acquires 100% Stake in Gelcaps Exportadora De Mexico 83

Perrigo Company Acquires Banner Pharmacaps from Patheon for USD36.4 Million 84

Perrigo Acquires Omega Pharma for USD4.76 Billion 85

Perrigo Acquires Remaining 15% Stake in Vedants Drugs & Fine Chemicals 87

Perrigo To Acquire 7% Stake In Transition Therapeutics For USD 15 Million 88

Perrigo Completes Acquisition Of Elan 89

Perrigo Acquires Rosemont Pharma From Close Brothers Private Equity For USD 284 Million 91

Omega Pharma Acquires Naturoteek 93

Perrigo Acquires Remaining 81.5% Stake In Cobrek Pharma For USD 45 Million 94

Couckinvest Completes Acquisition Of Remaining Stake In Omega Pharma For USD 1.26 Billion 95

Perrigo Acquires CanAm Care, Distributor Of Diabetes Care Products, For USD 36 Million 97

Perrigo Company Plc, Key Competitors 98

Perrigo Company Plc, Key Employees 99

Perrigo Company Plc, Subsidiaries 100

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Perrigo Company Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.